Document Detail

Current and future challenges in primary Sjögren's syndrome.
MedLine Citation:
PMID:  22208656     Owner:  NLM     Status:  Publisher    
Sjögren's syndrome (SS) is an autoimmune inflammatory disorder of exocrine glands. SS particularly affects the lacrimal and salivary glands. Dry mouth and dry eyes are frequently proffered as presenting symptoms, but non-specific symptoms such as malaise and fatigue, and extraglandular manifestations like purpura, polyneuropathy and arthritis are also often present. Moreover, lymphomas develop in about 7.5% of SS patients, mostly marginal zone B-cell lymhomas. Futhermore, SS has a very substantial impact on the patients' quality of life and their daily activities. Recently, many breakthroughs have been seen in salivary diagnostics, which not only can be used for diagnosis but also for monitoring of disease activity and disease progression as well as for objectively scoring the effect of intervention treatment with biologicals. In addition, salivary proteomics, genomics and system biology have been shown to be very promising tools in unravelling the pathophysiology of SS, thus providing in depth insight in its underlying mechanisms which could give clues for intervention therapies with biologicals. The latter is of particular interest as B cell depletion therapy has been shown a very promising therapy for a subgroup of SS patients. When applying salivary diagnostics in combination with instruments to rate disease activity and progression in SS, one might be able to select those SS patients who respond to a particular type of biological. These topics are addressed in this review and promises for the near future are described.
Arjan Vissink; Hendrika Bootsma; Fred Kl Spijkervet; Shen Hu; David T Wong; Cees Gm Kallenberg
Related Documents :
21943066 - Clinical prediction rules for invasive candidiasis in the icu: ready for prime time?
16966266 - Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis.
22221516 - Radionuclide therapy in neuroendocrine tumours: a systematic review.
21296606 - Botulinum toxin type a for the treatment of gastroparesis in parkinson's disease patients.
15551276 - Initial increase in the cryoglobulin level after rituximab therapy for type ii cryoglob...
20543416 - Brace prescription patterns in patients referred to orthopaedic clinics for adolescent ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-2
Journal Detail:
Title:  Current pharmaceutical biotechnology     Volume:  -     ISSN:  1873-4316     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960530     Medline TA:  Curr Pharm Biotechnol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Rheumatology and Clinical Immunology, AA21 University Medical Center Groningen, PO-Box 30.001 , 9700 RB Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Primary Sjögren's syndrome : time for prospective cohorts.
Next Document:  Primary Sjögren's syndrome and the type I interferon system.